Minerva Neurosciences, Inc.
NERVNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for NERV. That does not mean none is planned.
Get an email about NERV's next catalysts
Track Minerva Neurosciences (NERV) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 2 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Roluperidone | Phase 3 | Negative Symptoms of Schizophrenia | - | - |
MIN-117 | Phase 2 | Major Depressive Disorder | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Minerva Neurosciences, Inc.'s drug pipeline?β
CatalystAlert tracks 2 drug candidates in Minerva Neurosciences, Inc.'s (NERV) pipeline across Phase 3, Phase 2. Its lead program is Roluperidone (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Minerva Neurosciences, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Minerva Neurosciences, Inc. (NERV) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track NERV biotech catalysts?β
Add NERV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Minerva Neurosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
